$-0.34 EPS Expected for Vital Therapies, Inc. (VTL); Corbus Pharmaceuticals Holdings (CRBP) Shorts Increased By 3.21%

April 20, 2018 - By Ellis Scott

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Logo

Analysts expect Vital Therapies, Inc. (NASDAQ:VTL) to report $-0.34 EPS on May, 8.They anticipate $0.05 EPS change or 12.82% from last quarter’s $-0.39 EPS. After having $-0.35 EPS previously, Vital Therapies, Inc.’s analysts see -2.86% EPS growth. The stock decreased 3.45% or $0.2 during the last trading session, reaching $5.6. About 136,394 shares traded. Vital Therapies, Inc. (NASDAQ:VTL) has risen 69.62% since April 20, 2017 and is uptrending. It has outperformed by 58.07% the S&P500.

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) had an increase of 3.21% in short interest. CRBP’s SI was 8.96M shares in April as released by FINRA. Its up 3.21% from 8.68 million shares previously. With 762,500 avg volume, 12 days are for Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)’s short sellers to cover CRBP’s short positions. The SI to Corbus Pharmaceuticals Holdings Inc’s float is 20.57%. The stock decreased 1.11% or $0.075 during the last trading session, reaching $6.675. About 199,826 shares traded. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has declined 38.80% since April 20, 2017 and is downtrending. It has underperformed by 50.35% the S&P500.

Since December 12, 2017, it had 1 insider purchase, and 0 sales for $548,335 activity. Another trade for 100,000 shares valued at $548,335 was bought by Satter Muneer A.

Vital Therapies, Inc., a biotherapeutic company, focuses on developing a human hepatic cell therapy targeting the treatment of acute forms of liver failure in the United States. The company has market cap of $237.27 million. The Company’s ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patient's own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant. It currently has negative earnings. The firm was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003.

Investors sentiment increased to 2.85 in 2017 Q4. Its up 2.03, from 0.82 in 2017Q3. It improved, as 5 investors sold Vital Therapies, Inc. shares while 8 reduced holdings. 18 funds opened positions while 19 raised stakes. 10.42 million shares or 7.92% more from 9.66 million shares in 2017Q3 were reported. Credit Suisse Ag reported 0% stake. Raymond James And invested 0% of its portfolio in Vital Therapies, Inc. (NASDAQ:VTL). Susquehanna Grp Llp reported 0% of its portfolio in Vital Therapies, Inc. (NASDAQ:VTL). Wells Fargo & Mn accumulated 0% or 675 shares. Meeder Asset Mngmt holds 0% in Vital Therapies, Inc. (NASDAQ:VTL) or 760 shares. Morgan Stanley reported 0% stake. State Street Corp holds 0% or 30,870 shares. Citigroup Incorporated owns 1,333 shares for 0% of their portfolio. Tower Capital Ltd (Trc) has invested 0.01% in Vital Therapies, Inc. (NASDAQ:VTL). Northern Trust Corporation holds 0% or 74,695 shares. Balasa Dinverno & Foltz Limited accumulated 25,625 shares. 31,795 were accumulated by Barclays Public Ltd Limited Liability Company. 990,828 are owned by Blackrock. Balyasny Asset Mgmt Ltd Liability accumulated 10,200 shares or 0% of the stock. Gru One Trading L P owns 0% invested in Vital Therapies, Inc. (NASDAQ:VTL) for 2,000 shares.

Among 7 analysts covering Vital Therapies Inc (NASDAQ:VTL), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Vital Therapies Inc had 12 analyst reports since August 7, 2015 according to SRatingsIntel. BTIG Research initiated it with “Buy” rating and $23 target in Friday, August 7 report. The firm earned “Neutral” rating on Monday, October 26 by BTIG Research. The firm has “Buy” rating given on Monday, August 24 by SunTrust. The rating was downgraded by William Blair on Monday, August 24 to “Outperform”. Suntrust Robinson downgraded the shares of VTL in report on Monday, August 24 to “Neutral” rating. The firm has “Neutral” rating given on Tuesday, September 29 by SunTrust. Credit Suisse reinitiated Vital Therapies, Inc. (NASDAQ:VTL) on Monday, August 10 with “Outperform” rating. Canaccord Genuity maintained the stock with “Buy” rating in Monday, August 24 report. Credit Suisse downgraded Vital Therapies, Inc. (NASDAQ:VTL) on Monday, August 24 to “Neutral” rating. The rating was downgraded by Suntrust Robinson on Tuesday, September 29 to “Neutral”.

Among 5 analysts covering Corbus Pharma (NASDAQ:CRBP), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corbus Pharma had 21 analyst reports since September 8, 2015 according to SRatingsIntel. As per Thursday, January 18, the company rating was initiated by Raymond James. The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) earned “Buy” rating by Noble Financial on Friday, November 10. The firm has “Buy” rating given on Tuesday, August 8 by Noble Financial. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, December 14. The firm has “Buy” rating given on Tuesday, June 13 by Cantor Fitzgerald. The company was maintained on Monday, March 12 by Cantor Fitzgerald. The firm has “Buy” rating given on Wednesday, August 9 by Cantor Fitzgerald. Noble Financial maintained the shares of CRBP in report on Friday, November 11 with “Buy” rating. Cantor Fitzgerald maintained Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) on Wednesday, September 20 with “Buy” rating. The rating was initiated by Aegis Capital with “Buy” on Monday, March 7.

Vital Therapies, Inc. (NASDAQ:VTL) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>